Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results

Genetics Investing

Cambrex (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year. Excluding the impact of foreign …

As quoted in the press release:

Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year. Excluding the impact of foreign exchange, net revenue increased 1%. Full year net revenue increased 9% to $534.5 million, compared to $490.6 million in the full year 2016.

Click here to read the full press release.

apis cambrex full year 2016 generic pharmaceutical ingredients Genetics Investing